Clinical Evaluation of 532-nm Green Laser on Dentin Hypersensitivity: A Randomized Double-Blind Clinical Trial

2021 ◽  
Vol 39 (11) ◽  
pp. 705-710
Author(s):  
Su-Ning Hu ◽  
Lin-Tian Yuan ◽  
Meng-Qi Wang ◽  
Yu-Guang Wang ◽  
Yong-Sheng Zhou
Keyword(s):  
Clinical Trial ◽  
Clinical Evaluation ◽  
Green Laser ◽  
Dentin Hypersensitivity ◽  
Double Blind ◽  
Double Blind Clinical Trial ◽  
532 Nm

Combination of two desensitizing protocols to control dentin hypersensitivity in non-carious lesions: a randomized, double-blind clinical trial

2021 ◽  
Author(s):  
Antonia Patricia Oliveira Barros ◽  
Cristiane de Melo Alencar ◽  
Alexandra de Melo Pingarilho Carneiro ◽  
Danielle da Silva Pompeu ◽  
Gabriela Monteiro Barbosa ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Dentin Hypersensitivity ◽  
Double Blind ◽  
Double Blind Clinical Trial ◽  
Carious Lesions

scholarly journals Long-Term Effectiveness of Treating Dentin Hypersensitivity with Bifluorid 10 and Futurabond U: A Split-Mouth Randomized Double-Blind Clinical Trial

2021 ◽  
Vol 10 (10) ◽  
pp. 2085
Author(s):  
Marta Mazur ◽  
Maciej Jedliński ◽  
Artnora Ndokaj ◽  
Roman Ardan ◽  
Joanna Janiszewska-Olszowska ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Pain Reduction ◽  
Similar Efficacy ◽  
Negative Influence ◽  
Dentin Hypersensitivity ◽  
Double Blind ◽  
Double Blind Clinical Trial ◽  
Definition Of

Background: The definition of dental hypersensitivity is “pain derived from exposed dentin in response to chemical, thermal tactile or osmotic stimuli which cannot be explained as arising from any other dental defect or disease”. One of the treatments proposed is tubular occlusion. The aim of this in vivo split-mouth randomized clinical trial was to evaluate the clinical efficacy of a in-office application of a fluoride varnish (Bifluorid 10) and a bonding resin (Futurabond U) in adults with dentin hypersensitivity. Material and methods: A total of 180 teeth were treated with Bifluorid 10 and 160 with Futurabond U. Outcome measurements were taken one or two weeks before treatment, at baseline at the application days, at 1 week and at 1–6 months after first treatment. Results: Both treatments reduced pain intensity. Bifluorid 10 and Futurabond U have similar efficacy in reducing SCHIFF-measured pain reduction, while Bifluorid 10 is significantly more efficient for VAS-measured pain reduction, mainly due to long-term pain reduction. Patient age has a significant negative influence on pain reduction, while the influence of patient gender and BEWE of the tooth is insignificant. Conclusions: Bifluorid 10 and Futurabond U are effective in the treatment of dental hypersensitivity. The RCT was registered at the US National Institutes of Health (ClinicalTrials.gov) #NCT04813848.

A Non-Amphetamine Anorectic Agent: Preclinical Background and a Double-Blind Clinical Trial

1975 ◽  
Vol 3 (5) ◽  
pp. 328-332 ◽  
Author(s):  
Louis N Schwartz
Keyword(s):  
Clinical Trial ◽  
Weight Loss ◽  
Adverse Effects ◽  
Clinical Evaluation ◽  
Comparative Trial ◽  
Obese Patients ◽  
Double Blind ◽  
Once Daily ◽  
Double Blind Clinical Trial ◽  
Anorectic Agent

Preclinical data suggesting potential advantages for mazindol prompted the design of a double-blind comparative trial with 60 obese patients. In it, mazindol, 2 mg once a day, was compared for 12 weeks to placebo. Weight loss was significantly greater with mazindol than placebo throughout the trial. After the 12 weeks, the mazindol patients had lost an average of 18.5 lbs compared to 2.4 lbs with placebo. Constant efficacy at the fixed once-daily dosage was obtained with no signs of tolerance. No significant adverse effects or other signs of toxicity to mazindol were encountered. Extensive clinical evaluation of this drug in relation to the established anorectics is strongly recommended.

Sign in / Sign up

Export Citation Format

Share Document